AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/28/23

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) stock rose ~8% on Tuesday after Q4 net loss narrowed and revenue grew Y/Y. Net loss was -$26.05M, compared to -$33.32M in Q4 2021. Total net revenue grew +21.5% Y/Y to ~$28.44M, however it missed analysts estimates. Full year 2...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.18 beats by $0.09 . Revenue of $28.4M (+21.4% Y/Y) misses by $0.42M . Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022. For fiscal year 2023, the Company is reiterati...

$28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022 Conference call to be hosted t...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.27 (vs. -$0.25 last year) and the consensus Revenue Estimate is $28.82M (+23.2% Y/Y). Over the last 1 year, AUPH ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference. Oppenheimer 33rd Annual Virtual Healthcare Conference being he...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open. Aurinia’s management team will host a conference call/webcas...

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036. ...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its lupus nephritis therapy Lupkynis. The U.S. patent relates to the dosing regimen of Lu...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Appl...